Redcare Pharmacy's Leadership Overhaul Meets a Pivotal Policy Moment

Redcare Pharmacy's stock surged by double digits on Wednesday, a rare bright spot in what has been a punishing year for the German online pharmacy. The jump coincided with the company's Annual General Meeting, an event that formally installed a new leadership team tasked with navigating fierce competition and capitalizing on a potential regulatory tailwind.

The focal point of the shareholder meeting was the official appointment of Hendrik Krampe as the new Chief Financial Officer. Krampe brings two decades of e-commerce finance experience, most recently serving for eight years as Finance Director for Amazon’s European marketplace business, preceded by a stint at eBay. His expertise in scaling online platforms is seen as strategically vital for Redcare's next phase. The supervisory board is also undergoing a refresh, with Anja Hendel, Max Müller, and Peter Schmid von Linstow nominated to replace three long-standing members.

This management reshuffle is a direct response to mounting competitive pressures. The landscape intensified last December when German drugstore chain dm launched its own online pharmacy, "dm-med." While competition in the over-the-counter (OTC) segment has sharpened, Redcare's prescription (Rx) business remains a bastion of relative stability. The company holds a commanding 67% market share in German online Rx sales and is targeting revenue of over €670 million from this segment in 2026. Competitor Rossmann has explicitly ruled out entering the prescription market, solidifying Redcare's structural advantage there.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

Despite this core strength, the stock's performance has been dismal. Since January, shares have plummeted approximately 40%, placing Redcare second-to-last on the MDAX index of German mid-caps, trailing only Auto1 Group. The current price sits more than 70% below its 52-week high of €136.20. Analyst sentiment, however, remains cautiously optimistic; nine covering analysts predominantly recommend buying the stock, with an average price target near €95.

A significant potential catalyst for the online pharmacy sector is brewing in Berlin. A government-appointed expert commission has recommended raising statutory co-payments for prescription medicines by 50%, from the current range of €5-€10 to a new band of €7.50-€15 per prescription. Health Minister Nina Warken has pledged to advance corresponding legislation swiftly. Bankhaus Metzler analyst Felix Dennl argues this reform would benefit mail-order pharmacies, as cost-sensitive patients are likely to seek out cheaper online alternatives when faced with higher out-of-pocket expenses.

The first real test for the new executive team arrives on May 6th with the release of Redcare's first-quarter results. Investors will scrutinize whether the company remains on track to meet its full-year targets of 13-15% revenue growth and an adjusted EBITDA margin of at least 2.5%. The report will reveal if growth in the resilient Rx business can sufficiently offset the ongoing challenges in the competitive OTC segment.

Ad

Redcare Pharmacy Stock: New Analysis - 13 April

Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Redcare Pharmacy analysis...

en | NL0012044747 | REDCARE | boerse | 69135427 |